Crimson Investment: Small companies. Bigger maps.

A breast pump is a machine. To an investor, it can also be the beginning of a relationship. A hospital installs the equipment. Families become familiar with the brand. Collection kits and accessories create reasons to buy again. When Crimson Investment bought Ameda from Evenflo, its financing partner highlighted precisely those features: hospital relationships, retail distribution, and recurring accessory revenue. The interesting asset was bigger than the object in the box.

That is a useful introduction to a firm whose historical investments include breast pumps, pneumatic accessories, and water purification systems. These products have little visual resemblance. Commercially, they raise similar questions. Who already trusts them? What keeps a customer buying? And what would happen if a capable business could reach customers beyond its familiar territory?

01 / A business with somewhere to go

Crimson supplies buyout and growth capital to middle-market companies. Its public description names industrial, manufacturing, healthcare, and consumer businesses, with a target of $5 million to $50 million in annual EBITDA. That measure is earnings before interest, taxes, depreciation, and amortization. It describes the operating scale Crimson seeks, rather than the price it pays for a company.

The distinction matters. This is a strategy built around businesses with something already functioning: products, customers, and managers. An owner seeking a change in ownership, or a management team seeking money to expand, supplies one side of the relationship. Crimson supplies capital and an operating proposition. ACG’s biography of co-managing partner Ian Morton describes that proposition concretely: acquire U.S. businesses and help management establish capabilities and sales in Asia.

The investment business sits behind those operating companies. Funds own stakes; an eventual sale can realize investment gains. For the company manager, however, the practical issue comes earlier. Capital can finance an expansion. It cannot, by itself, tell somebody how to run it.

02 / The first obstacle was trust

John-Paul Ho founded Crimson in 1993. Early mainland-China opportunities disappointed him on management quality, so he pursued other Asian markets before investing on the mainland in 1998. His eventual approach emphasized helping established manufacturers build operations there. The geography remained attractive. The kind of business he wanted to own changed.

That history suggests a useful discipline: separate enthusiasm for a market from confidence in the people operating within it. A promising location does not make every local company an attractive acquisition. For a business owner, the copyable question is simple enough to put on one page: which missing capability will this partner actually bring?

Morton’s responsibilities have included investment committee membership and chairing portfolio companies. Those roles put the investor close to decisions after the transaction. They also explain why management relationships recur in Crimson’s description of itself. Buying a business is a moment. Working with its managers is an arrangement that has to survive many ordinary Tuesdays.

03 / Follow the accessory

Ameda makes the logic unusually easy to see. In January 2013, Maranon Capital announced that it had supplied senior debt, mezzanine debt, and equity alongside Crimson for the acquisition. Ameda’s breast pumps and accessories were sold through retailers in more than 40 countries. Maranon pointed to the installed hospital base and recurring purchases of accessories as attractions.

There were several commercial relationships inside that one business: with healthcare facilities, with retailers, and with families. The inference is straightforward. A product with a durable route to its customer can offer more room for expansion than its initial sales suggest. Distribution and repeat purchases deserve their own place in the investment analysis.

“Ameda is Maranon’s second investment in partnership with Crimson since June 2012.”

Tom Gregory, Maranon Capital · January 2013

The financing also gives substance to Crimson’s stated conservatism about leverage. Debt was part of this transaction. The claim is that operational improvements and globalization should generate most of the value. The financing announcement identifies the instruments involved; it should not be mistaken for a disclosed borrowing ratio.

Ameda’s next ownership chapter arrived in January 2023, when International Biomedical announced the acquisition. The buyer described a fit with its neonatal and perinatal equipment offering. It said the two businesses would continue operating independently. A specialist product business could complement a broader supplier while retaining its own identity.

04 / Three products. Three next chapters.

Milton Industries supplies another version of that commercial depth. When Crimson sold it to Levine Leichtman Capital Partners in November 2019, Milton had more than 1,600 SKUs. The catalog included couplers, gauges, filters, regulators, and lubricators for markets ranging from vehicle service to aerospace and agriculture. Each modest component belonged to a larger working system.

Aqua-Chem offered specialized water purification equipment. Crimson acquired it from Altus Capital Partners in 2014. Saur completed its purchase in May 2022, making Aqua-Chem its North American industrial-water platform. At announcement, Saur described more than 300 customers and technologies including vapor compression distillation and reverse osmosis. It saw opportunities in cross-selling, services, manufacturing, and technical collaboration.

Those are a buyer’s stated opportunities, not proof that every expected benefit materialized. They do show what a specialist can contribute to a larger owner. The equipment, customer relationships, and technical knowledge travel together.

Read together, the three exits offer a useful comparison of potential owners. A financial sponsor such as LLCP brings another investment partnership. A strategic buyer such as Saur or International Biomedical can place a specialist inside an existing product and customer network. For managers considering a sale, that difference deserves attention alongside the offer price. The next owner’s capabilities help determine which expansion plans are plausible, which relationships matter most, and how much independence the business needs to keep.

05 / Take the question, not the itinerary

Other middle-market sponsors can also provide capital and operating help. Crimson’s distinctive emphasis is the international connection. The useful lesson from its history is to identify a business’s existing strengths, then ask which additional capability could make them valuable elsewhere.

That logic has conditions. As an operating inference, expansion becomes harder when customer demand is unproven, management is unreliable, or distance adds more complexity than commercial advantage. A bigger market cannot repair an unsuitable business. For owners weighing a partner, the test is concrete: name the capability, name the people responsible, and explain why customers will care. That is where the map becomes a business plan.